Mavorixafor + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
WHIM Syndrome
Conditions
WHIM Syndrome
Trial Timeline
Oct 24, 2019 → Dec 1, 2025
NCT ID
NCT03995108About Mavorixafor + Placebo
Mavorixafor + Placebo is a phase 3 stage product being developed by X4 Pharmaceuticals for WHIM Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT03995108. Target conditions include WHIM Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06056297 | Phase 3 | Recruiting |
| NCT03995108 | Phase 3 | Active |
Competing Products
1 competing product in WHIM Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| X4P-001 | X4 Pharmaceuticals | Phase 2 | 44 |